Press coverage about Kadmon Holdings (NASDAQ:KDMN) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Kadmon Holdings earned a news impact score of 0.12 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.4912040450235 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Analyzing Kadmon Holdings (KDMN) and Ocera Therapeutics (OCRX) (americanbankingnews.com)
- Kadmon : FDA Grants Orphan Drug Designation to Kadmon’s KD025 for the Treatment of cGVHD (4-traders.com)
- AcelRx Pharmaceuticals, Inc. (ACRX) is at $5.20 per share and Kadmon Holdings, Inc. (KDMN) is listed at $3.70 – Stocks Gallery (stocksgallery.com)
- Featured Company News – Kadmon Holdings’ KD025 Receives Orphan Drug Designation for the Treatment of cGVHD by FDA (finance.yahoo.com)
- Advice by Analysts to Buy Healthcare Stock: Kadmon Holdings, Inc. (KDMN) – Street Observer (press release) (streetobserver.com)
Shares of Kadmon Holdings (KDMN) traded down 6.6696% during mid-day trading on Friday, reaching $3.2199. 428,023 shares of the company traded hands. The firm’s 50 day moving average price is $3.42 and its 200-day moving average price is $3.42. The company’s market capitalization is $166.94 million. Kadmon Holdings has a 52-week low of $2.86 and a 52-week high of $7.10.
Kadmon Holdings (NASDAQ:KDMN) last released its quarterly earnings results on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The company had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $3.46 million. The firm’s revenue was down 53.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($4.40) EPS. Equities analysts predict that Kadmon Holdings will post ($1.55) earnings per share for the current fiscal year.
KDMN has been the subject of several recent research reports. WBB Securities lowered shares of Kadmon Holdings from a “hold” rating to a “sell” rating and set a $3.00 price objective for the company. in a research note on Monday. Piper Jaffray Companies set a $7.00 price objective on shares of Kadmon Holdings and gave the company a “buy” rating in a research note on Wednesday, August 2nd. ValuEngine lowered shares of Kadmon Holdings from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Kadmon Holdings in a research note on Monday, June 26th. Finally, Zacks Investment Research lowered shares of Kadmon Holdings from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Kadmon Holdings presently has an average rating of “Hold” and a consensus target price of $9.80.
ILLEGAL ACTIVITY NOTICE: “Kadmon Holdings (KDMN) Given Daily News Sentiment Rating of 0.12” was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.truebluetribune.com/2017/10/13/kadmon-holdings-kdmn-given-daily-news-sentiment-rating-of-0-12.html.
In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $2.73, for a total value of $827,053.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders acquired 14,707 shares of company stock valued at $34,294.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.